OMEICOS Therapeutics raises €8.3M Series B round

1 March 2017· Berlin, Germany· health, biotech, materials, b2b, deep_hardware

The funding will support the newly initiated Phase 1 clinical program for lead compound OMT-28 and further leverage the therapeutic potential of the technology

Investors

LeadVesalius Biocapital II

Also participating

SMS groupKfW GroupVC Fonds Technologie BerlinHigh-Tech Gründerfonds IIThe Falck Revocable TrustAscenion

About OMEICOS Therapeutics

Stage

Series C

Headquarters

Berlin, Germany

Founded

2013

Team Size

6–20

Sectors

healthbiotechmaterialsb2bdeep_hardware

https://www.omeicos.com/

Source: https://www.omeicos.com/news/press-releases/omeicos-announces-first-closing-of-83-million-series-b-financing-round-and-the-initiation-of-phase-1-clinical-trial/